Yatai Pharmaceutical to Establish Subsidiary for Pioneering Photodynamic Drug and Device Development

Stock News
06/11

Zhejiang Yatai Pharmaceutical Co.,Ltd. (SHE: 002370) has announced plans to establish a new subsidiary, a strategic move aimed at expanding its industrial footprint.

The company's wholly-owned subsidiary, Yatai Lizhong, intends to use its own funds of 20 million yuan to set up Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (tentative name).

This initiative is part of the company's strategic and operational planning, designed to further refine its industrial development layout.

Photodynamic therapy (PDT) is a medical technique that utilizes photosensitizers, specific wavelengths of light, and oxygen molecules to destroy diseased tissue. It is widely used in cancer treatment, dermatology, and certain inflammatory diseases, representing a cutting-edge field in the healthcare industry.

The core principle involves activating photosensitizers within the lesion using light, generating reactive oxygen species to kill target cells. This method offers advantages such as precise targeting, minimal invasiveness, and rapid recovery.

In recent years, advancements in photosensitizing substances, light sources, and light delivery systems have propelled PDT forward. Its low toxicity, protective effects on organ function, and unique clinical advantages in treating superficial proliferative lesions on body surfaces and in cavities have established it as a significant treatment for tumors and various benign conditions.

The investment is driven by the company's strategic planning and future development needs. It represents an active move to enter the new field of photodynamic therapy.

By leveraging its existing business foundation and resource advantages, the company aims to integrate industrial resources related to photodynamics. The focus will be on strengthening the research, development, and industrialization of photodynamic drugs.

A key objective is to explore the development of innovative photodynamic drugs and their supporting medical devices.

This effort is expected to cultivate new business growth points for the company, optimize its business structure, enhance overall profitability and core competitiveness, and promote long-term sustainable development.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10